Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

P. Frias, Juan; G. Wynne, Alan; Matyjaszek‐Matuszek, Beata; Bartaskova, Dagmar; A. Cox, David; Woodward, Brad; G. Li, Ying; S. Tham, Lai; Milicevic, Zvonko

doi:10.1111/dom.13764

Public

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

Shared by NobleBlocks on Jun 3, 2019 • 12:00 AM UTC

Authors:

Juan P. Frias

Alan G. Wynne

Beata Matyjaszek‐Matuszek

Abstract

Abstract Aims Dulaglutide, a once weekly GLP‐1 receptor agonist, is approved at two doses (1.5 and 0.75 mg) for treatment of type 2 diabetes (T2D). Two higher doses of dulaglutide (3.0 and 4.5 mg) were evaluated for safety and efficacy to determine whether these doses warrant further study for impro...

Discussions